- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07859878
Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis (HILT-ESCOA)
Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial
This randomized, double-blind, sham-controlled clinical trial evaluated the effectiveness of high-intensity laser therapy (HILT) in patients with early-stage symptomatic knee osteoarthritis.
A total of 39 participants were randomly assigned to receive either HILT combined with a standardized home exercise program or sham laser therapy combined with the same exercise program. Laser or sham treatment was administered over 10 weekday sessions during a two-week period.
Participants were assessed at baseline, immediately after treatment, and at the three-month follow-up. Assessments included pain intensity, physical function, health-related quality of life, walking performance, knee range of motion, and muscle strength.
The aim was to determine whether adding HILT to exercise provides additional clinical benefits compared with sham laser therapy combined with exercise.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
İzmir
-
Izmir, İzmir, Turquie (Türkiye), 35100
- Ege University Faculty of Medicine Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Inclusion Criteria:
- Patients presenting to the Physical Medicine and Rehabilitation outpatient clinics of Ege University Faculty of Medicine Hospital with knee pain lasting no longer than 6 months and a Visual Analog Scale (VAS) pain score of at least 4.
- Availability of bilateral weight-bearing knee radiographs in two views obtained within the preceding 6 months.
- Diagnosis of early symptomatic knee osteoarthritis according to the Italian Society of Rheumatology International Initiative (ESKOA) criteria.
- Ability to cooperate with the prescribed exercise program.
- Willingness to participate in the study and provision of informed consent.
- Age eligibility:
-
40-49 years: Presence of at least one of the following risk factors for early symptomatic knee osteoarthritis.
-
50-75 years: Eligible regardless of the presence of the listed risk factors.
Risk factors:
- Body mass index (BMI) greater than 25 kg/m².
- Family history of knee osteoarthritis.
- Previous knee injury.
- Lower-limb alignment abnormality.
- Lower-limb length discrepancy.
- Osteoarthritis at other anatomical sites.
- Metabolic syndrome.
- Difficulty initiating brisk walking or running after a period of inactivity.
Exclusion Criteria:
-
Receipt of an intra-articular knee injection or physical therapy within the preceding 6 months, or use of natural health products such as glucosamine or chondroitin.
-
History of knee surgery.
-
Presence of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or gouty arthritis.
-
History of trauma within the preceding 6 months.
-
Fixed knee flexion deformity greater than 10 degrees or varus/valgus deformity greater than 15 degrees.
-
Referred pain originating from the lumbar spine or hip.
-
Neurological deficits affecting the lower extremities.
-
Medical conditions that could prevent participation in the exercise program or completion of the study, including:
- Myocardial infarction or cerebrovascular event within the preceding 3 months.
- Congestive heart failure.
- Severe chronic obstructive pulmonary disease.
- History of myocardial ischemia during treadmill testing.
- History of arterial or venous circulatory disorders.
-
Presence of a cardiac pacemaker or metal implants.
-
Pregnancy.
-
History of malignancy, knee osteonecrosis, infectious disease, psychiatric illness, or bleeding diathesis.
-
Epilepsy.
-
Conditions impairing cooperation or communication, including language barriers, aphasia, marked affective disorders, or a history of severe psychiatric illness.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: HILT + Exercise
Participants received high-intensity laser therapy (HILT) combined with a standardized home exercise program. HILT was administered in 10 sessions over two consecutive weeks (five sessions per week). Participants also performed the prescribed home exercise program throughout the treatment period. |
High-intensity laser therapy (HILT) was administered using a 1064-nm laser at a frequency of 20 Hz, with an energy density of 1530 mJ/cm² and a total energy of 3000 J per session. Treatment consisted of 10 sessions administered on consecutive weekdays over a two-week period. HILT was combined with a standardized home exercise program. Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment. |
|
Comparateur factice: Sham Laser + Exercise
Participants received sham laser therapy combined with the same standardized home exercise program as the experimental group. The sham procedure was administered without therapeutic laser energy in 10 sessions over two consecutive weeks (five sessions per week). |
Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment. Sham laser therapy was administered using the same treatment schedule and application procedure as the active HILT group, but without delivering therapeutic laser energy. Participants received 10 sham sessions over two consecutive weeks (five sessions per week), combined with the same standardized home exercise program. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain Intensity Assessed by Visual Analog Scale (VAS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Pain intensity was assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Knee Symptoms and Physical Function Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Knee osteoarthritis-related symptoms and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), including pain, stiffness, and physical function subscales. Higher scores indicate greater symptom severity and functional impairment. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional Status Assessed by Health Assessment Questionnaire (HAQ)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Functional status and activities of daily living were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). Scores range from 0 to 3, with higher scores indicating greater disability and poorer functional status. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Physical Component Summary (PCS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Physical health-related quality of life was assessed using the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better physical health-related quality of life. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Mental Component Summary (MCS)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Mental health-related quality of life was assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional Exercise Capacity Assessed by 6-Minute Walk Test (6MWT)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Functional exercise capacity was assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes was recorded in meters. A greater walking distance indicates better functional exercise capacity. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Knee Range of Motion (ROM)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Knee range of motion was assessed using a goniometer. Active and passive knee range of motion were measured in degrees. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Lower Extremity Muscle Strength Assessed by Manual Muscle Testing (MMT)
Délai: Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
Lower extremity muscle strength was assessed using manual muscle testing (MMT). Muscle strength was graded on a 0-to-5 scale, with higher scores indicating greater muscle strength. |
Baseline, immediately after the 2-week treatment period, and 3 months after baseline
|
|
Paracetamol Use
Délai: Throughout the study period, from baseline to the 3-month follow-up
|
Paracetamol use was monitored using a patient diary to assess analgesic use during the study. Changes in paracetamol use were evaluated as an additional indicator of treatment effectiveness. |
Throughout the study period, from baseline to the 3-month follow-up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: A.Simin Hepgüler, MD, Ege University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EGE-PMR-HILT-2025-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval.
Délai de partage IPD
De-identified individual participant data will be available upon reasonable request following publication of the manuscript.
Critères d'accès au partage IPD
De-identified individual participant data may be shared with qualified researchers upon reasonable request to the corresponding author (silaolmez@yahoo.com.tr), subject to ethical and institutional approval.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .